CC
RNA

Corsicana & Co’s Atrium Therapeutics RNA Stock Holding History

Corsicana & Co’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132K Buy
+9,820
New +$128K 0.06% 111

Other funds holding RNA

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FI
Fractal Investments Glastonbury, Connecticut $867M AUM 23.63% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Corsicana & Co's RNA Position: Q2 2026 in Review

Corsicana & Co opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 9,820 shares worth $132K. The stake represents 0.06% of the portfolio and ranks #111 among its holdings.

19 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Corsicana & Co held 9,820 shares of Atrium Therapeutics worth $132K as of Q2 2026.
  • Atrium Therapeutics was a new Corsicana & Co position in Q2 2026.
  • Atrium Therapeutics made up 0.06% of Corsicana & Co's portfolio in Q2 2026, its #111 holding.
  • 19 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Corsicana & Co's 13F filing for Q2 2026, filed 24 Jul 2026.